SML0971
Ki 16425
≥98% (HPLC)
别名:
3-[[[4-[4-[[[1-(2-Chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]phenyl]methyl]thio]-propanoic acid, Ki16425
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
SMILES string
S(CCC(=O)O)Cc1ccc(cc1)c2[o]nc(c2NC(=O)OC(C)c3c(cccc3)Cl)C
InChI
1S/C23H23ClN2O5S/c1-14-21(25-23(29)30-15(2)18-5-3-4-6-19(18)24)22(31-26-14)17-9-7-16(8-10-17)13-32-12-11-20(27)28/h3-10,15H,11-13H2,1-2H3,(H,25,29)(H,27,28)
InChI key
LLIFMNUXGDHTRO-UHFFFAOYSA-N
Application
Ki 16425 has been used as a chemical inhibitor to study the regulation of LPA (lysophosphatidic acid) on LPAR(LPA receptor) subtypes.
Biochem/physiol Actions
Ki 16425 possesses a short-lived inhibitory activity. It has been studied that Ki 16425 is effective in the inhibition of neuropathic pain‐like behaviors.
Ki16452 is a potent antagonist of the lysophosphatidic acid receptors LPA1 and LPA3, with greater than 30-fold selectivity for LPA1 over LPA2. The Ki values for LPA1 and LPA3 are 250 nM and 360 nM, respectively.
Ki16452 is a potent antagonist of the lysophosphatidic acid receptors LPA1 and LPA3.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki?16425, a lysophosphatidic acid 1 receptor antagonist.
Ma L, et al.
Journal of Neurochemistry, 109(2), 603-610 (2009)
Chia-Hung Chou et al.
PloS one, 10(3), e0122060-e0122060 (2015-03-31)
Lysophosphatidic acid (LPA) is a multi-function glycerophospholipid. LPA affects the proliferation of hepatocytes and stellate cells in vitro, and in a partial hepatectomy induced liver regeneration model, the circulating LPA levels and LPA receptor (LPAR) expression levels in liver tissue
Jean-Philippe Pradère et al.
Journal of the American Society of Nephrology : JASN, 18(12), 3110-3118 (2007-11-16)
Tubulointerstitial fibrosis in chronic renal disease is strongly associated with progressive loss of renal function. We studied the potential involvement of lysophosphatidic acid (LPA), a growth factor-like phospholipid, and its receptors LPA(1-4) in the development of tubulointerstitial fibrosis (TIF). Renal
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0971-5MG | 04061837107450 |
| SML0971-25MG | 04061833224465 |